Scandinavian Journal of Rheumatology最新文献

{"title":"iPhone Compass for cervical rotation in ankylosing spondylitis: are we ready for clinical translation?","authors":"B Choudhuri","doi":"10.1080/03009742.2026.2719330","DOIUrl":"https://doi.org/10.1080/03009742.2026.2719330","url":null,"abstract":"","PeriodicalId":21424,"journal":{"name":"Scandinavian Journal of Rheumatology","volume":" ","pages":"1-3"},"PeriodicalIF":1.5,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148866674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Duration and dose of allopurinol needed to attain the serum urate target in gout.","authors":"T Uhlig, L F Karoliussen, J Sexton, E A Haavardsholm, S A Provan, D H Solomon, H B Hammer","doi":"10.1080/03009742.2026.2648357","DOIUrl":"10.1080/03009742.2026.2648357","url":null,"abstract":"<p><strong>Objective: </strong>To examine, in patients with gout using escalating urate-lowering therapy (ULT), the treatment duration and allopurinol dose required to attain the serum urate (SU) target (< 360 μmol/L; < 6 mg/dL).</p><p><strong>Method: </strong>We studied patients in the NOR-Gout prospective cohort with a recent gout flare and increased SU (> 360 μmol/L). Patients escalated allopurinol dosage until reaching the SU treatment target of <360 µmol/L, switching, if needed, to febuxostat.</p><p><strong>Results: </strong>Of 211 patients, 95.2% were male; mean ± sd age was 56.7 ± 13.7 years, disease duration 8.1 years, 16.6% had clinical tophi, and 12.8% used allopurinol at cohort entry. Mean SU (μmol/L) was reduced from 500 at baseline to 312 at 1 year and 325 at 2 years. Target SU was attained at least once during year 1 by 197 patients (93.4%). Median time to attaining the treatment target was 2 months (mean 2.9 months), and median allopurinol dose was 200 mg (mean 243 mg). Eighty per cent of patients reached the treatment target by 3 months. Patients with SU >480 μmol/L at baseline needed a median of 3 months to attain target SU versus 2 months for patients with SU <480 μmol/L (log-rank p < 0.001). A switch to febuxostat was seen in 12.4% at year 1 and 15.1% at year 2.</p><p><strong>Conclusion: </strong>Treat-to-target ULT using allopurinol leads to attainment of the SU target within 2-3 months at low doses for most patients. Very few patients did not achieve the treatment target at least once during year 1.</p><p><strong>Trial registration: </strong>ACTRN12618001372279.</p>","PeriodicalId":21424,"journal":{"name":"Scandinavian Journal of Rheumatology","volume":" ","pages":"352-357"},"PeriodicalIF":1.5,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147779812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Marked neurological recovery after severe Takayasu arteritis-associated cerebral infarction without revascularization: a case report.","authors":"K Izaki, M Fujimura, H Hara, R Tsutsumi, T Kogo, M Kojima","doi":"10.1080/03009742.2026.2712802","DOIUrl":"10.1080/03009742.2026.2712802","url":null,"abstract":"","PeriodicalId":21424,"journal":{"name":"Scandinavian Journal of Rheumatology","volume":" ","pages":"390-392"},"PeriodicalIF":1.5,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148813755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors associated with shorter time to death and causes of mortality among deceased patients with systemic sclerosis: a multicentre retrospective study.","authors":"M A Balcı, Z Yağbasan, I Gunduz, A N Bayindir Akbaş, F Albayrak, O Zengin, B Kısacık, B N Coşkun, L Akyol, E İnanç, A Gocer, D Tezcan, S Zontul, S Sunkak, A Kucuk, B Yağız, E Dalkilic, Y Pehlivan, S S Koca, A Karataş, S Yolbaş, Z A Akar, R Çevik, O Cüre, B Okyar, U Karasu, S Ermurat, E Keskin, Ö Kudaş, H Babaoğlu, H Harman, Ç Çetin, G Yildirim-Cetin","doi":"10.1080/03009742.2026.2700105","DOIUrl":"https://doi.org/10.1080/03009742.2026.2700105","url":null,"abstract":"<p><strong>Objective: </strong>To describe causes of death and identify clinical factors associated with shorter time to death among deceased patients with systemic sclerosis (SSc) in Turkey.</p><p><strong>Method: </strong>This retrospective multicentre study screened hospital databases across 19 tertiary rheumatology centres between 2004 and 2024 for deceased patients aged ≥16 years with ICD-10 codes beginning with M34. Eligibility was confirmed according to the 2013 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria; 266 of 294 identified patients were included. Dates of death were verified through the national death registry. Baseline clinical features, organ involvement, and key echocardiographic measures were extracted from medical records. Time to death was defined as the interval from diagnosis to death. Cause-specific Cox regression models were constructed for SSc-related and non-SSc-related deaths.</p><p><strong>Results: </strong>Of 266 deaths, 122 (45.9%) were SSc related and 144 (54.1%) non-SSc related. Among SSc-related deaths, interstitial lung disease (ILD) (50.0%, n = 61) and pulmonary arterial hypertension (PAH) (42.6%, n = 52) predominated. Among non-SSc-related deaths, cardiovascular causes (38.9%, n = 56), infections (33.3%, n = 48), and malignancy (19.4%, n = 28) were most frequent. In multivariable models, older age at diagnosis, scleroderma renal crisis, palpitations, ILD, and higher echocardiographic pulmonary artery systolic pressure were independently associated with shorter time to SSc-related death, whereas older age at diagnosis and malignancy were associated with shorter time to non-SSc-related death.</p><p><strong>Conclusion: </strong>Pulmonary complications predominated among SSc-related deaths, whereas cardiovascular disease, infections, and malignancy were the leading contributors to non-SSc-related mortality. These findings support systematic cardiopulmonary assessment and comorbidity management.</p>","PeriodicalId":21424,"journal":{"name":"Scandinavian Journal of Rheumatology","volume":" ","pages":"1-11"},"PeriodicalIF":1.5,"publicationDate":"2026-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148797826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Induction of type I and III interferons by viral and endogenous stimuli in systemic sclerosis.","authors":"S Adeli, Ö I Emilsson, E Hellbacher, K Hjorton, P Runeson, A Christias, P M Hellström, J Rönnelid, L Rönnblom, D Leonard, T Hansen, A Malinovschi, M-L Eloranta","doi":"10.1080/03009742.2026.2711485","DOIUrl":"https://doi.org/10.1080/03009742.2026.2711485","url":null,"abstract":"<p><strong>Objective: </strong>The interferon (IFN) system is activated in systemic sclerosis (SSc), and various stimuli may induce IFN in SSc patients. We investigated whether type I and III IFN responses to Toll-like receptor (TLR)-7/8/9 stimulation differ between patients with SSc and healthy individuals, and whether IFN production is associated with clinical features.</p><p><strong>Method: </strong>Peripheral blood mononuclear cells (PBMCs), monocyte-depleted PBMCs, and monocytes were prepared from 45 SSc patients and 47 healthy controls. Cells were stimulated with RNA-containing immune complexes (RNA-IC), an RNA oligonucleotide (ORN8L), or inactivated herpes simplex virus (HSV) targeting TLR7, TLR8, and TLR9, respectively. IFN-α, -β, -λ₁, and -λ₂ levels were measured by immunoassays, and intracellular IFN-α by flow cytometry.</p><p><strong>Results: </strong>SSc PBMCs produced type I and III IFNs in response to all three stimuli, with the strongest response following TLR9 activation. Compared with controls, SSc PBMCs produced less IFN-α (p < 0.02), whereas IFN-β levels were higher in SSc monocytes (342 vs 59.9 pg/mL, p = 0.041) when activated via TLR9. IFN-λ_1/2 levels were consistently lower than type I IFNs. IFN-α priming increased TLR7/8-induced IFN production in PBMCs. Strong TLR9-mediated IFN-α production was associated with diffuse cutaneous SSc, anti-RNA-polymerase III autoantibodies, and interstitial lung disease (ILD).</p><p><strong>Conclusion: </strong>Leucocytes from SSc patients produce type I and III IFNs in response to a broad range of TLR stimuli. IFN-α priming enhanced TLR7/8-induced IFN production, suggesting that strong IFN inducers, e.g. certain viruses, may amplify IFN synthesis in response to endogenous TLR ligands and contribute to SSc pathogenesis, including the development of ILD.</p>","PeriodicalId":21424,"journal":{"name":"Scandinavian Journal of Rheumatology","volume":" ","pages":"1-10"},"PeriodicalIF":1.5,"publicationDate":"2026-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148797183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A self-management app in a digital treat-to-target gout-care approach: the ReMonit Gout feasibility study.","authors":"J Stjärne, F Aanesen, S Søhus, A Abhishek, N Dalbeth, H B Hammer, E K Kristianslund, A T Tveter, T Uhlig, I J Berg, N Østerås","doi":"10.1080/03009742.2026.2706265","DOIUrl":"10.1080/03009742.2026.2706265","url":null,"abstract":"<p><strong>Objective: </strong>A self-management app, Urika, was developed to remotely monitor and support patients when initiating urate-lowering therapy (ULT). The objective was to test the overall feasibility of a future randomized controlled trial of a digital treat-to-target gout-care approach using Urika in secondary care.</p><p><strong>Method: </strong>Feasibility was tested among patients with gout in specialized healthcare over 3 months. The predefined set of feasibility criteria included aspects of technical, operational, and trial feasibility, as well as the feasibility of collecting clinical outcomes. Overall feasibility would be deemed acceptable if ≥ 70% of the predefined criteria were achieved. Patient participants entered their measured serum urate, ULT medication, start dose, and flare medication into the app. The app provided instructions about dose escalations. Patient characteristics and patient-reported outcome measures were collected by digital questionnaires, and app experiences were collected in semi-structured telephone interviews.</p><p><strong>Results: </strong>The study included 21 males aged 29-71 years. In total, 27/31 (87%) of the predefined feasibility criteria were achieved, 85% of patients rated their satisfaction with the app ≥ 8 on a 0-10 numeric rating scale, and 90% reported being satisfied/very satisfied with the gout treatment. Ten patients were interviewed, giving mainly positive feedback on the Urika app. No safety issues were identified in this small sample.</p><p><strong>Conclusion: </strong>The overall feasibility of the Urika app and the study logistics were satisfactory. The study results have been used to improve the app functions and decide study logistics in an ongoing randomized controlled trial of a digital treat-to-target gout-care approach.<b>Trial Registration Number</b>: ClinicalTrials.gov: NCT06211322, registered 18 January 2024.</p>","PeriodicalId":21424,"journal":{"name":"Scandinavian Journal of Rheumatology","volume":" ","pages":"1-13"},"PeriodicalIF":1.5,"publicationDate":"2026-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148721822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to the letter regarding 'Assessing cervical rotation in ankylosing spondylitis: iPhone Compass versus traditional tools'.","authors":"G Kenar Artin, H Yarkan Tugsal, B Akin, P Cetin, I Sari, N Akkoc","doi":"10.1080/03009742.2026.2706269","DOIUrl":"10.1080/03009742.2026.2706269","url":null,"abstract":"","PeriodicalId":21424,"journal":{"name":"Scandinavian Journal of Rheumatology","volume":" ","pages":"1-2"},"PeriodicalIF":1.5,"publicationDate":"2026-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148713477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patterns of migration underlie the increasing incidence of Kawasaki disease in Sweden from 1987 to 2018: a cohort study.","authors":"A Rudolph, J Mofors, A Frisk, B Schiller, G Elinder, F Nordenstam, H Eliasson, G Bergman, F Granath, M Wahren-Herlenius","doi":"10.1080/03009742.2026.2658353","DOIUrl":"10.1080/03009742.2026.2658353","url":null,"abstract":"<p><strong>Objective: </strong>To define the demographics of Kawasaki disease (KD) in Sweden during a 32 year period.</p><p><strong>Method: </strong>Routinely collected administrative and healthcare data from nationwide Swedish registers were collected for this population-based cohort study. The case definition was individuals under the age of 25 and diagnosed with KD from 1987 to 2018. Main measures included incidence rate, year and month of diagnosis, sex and age at diagnosis, patient's and parents' world region of birth, and home county.</p><p><strong>Results: </strong>In total, 1917 cases were identified. Median age at diagnosis was 2.82 years (interquartile range 1.47-5.13) and 62% were males. Relative incidence rates in winter [1.29, 95% confidence interval (CI) 1.14-1.47] and spring (1.21, 95% CI 1.07-1.38) were higher than in the reference season (summer), while incidence over the study period varied geographically across counties, with no discernible pattern. The incidence rate in the population increased during the 32 year period from 3.6 to 12.1 (95% CI 9.1-15.2) per 100 000 under-5-year-olds during the last 5 years of the study. This increase related mainly to cases with one or two parents of non-Swedish, predominantly Asian and African, origin. Two significant peaks in incidence rates in 2008 and 2015 were also observed, mainly relating to cases with two Swedish-born parents.</p><p><strong>Conclusion: </strong>Our study confirms the age and sex distribution as well as seasonal variation and occurrence of peak years of KD. Migration patterns were associated with increasing numbers of KD, which is important to consider for healthcare planning and for defining risk groups.</p>","PeriodicalId":21424,"journal":{"name":"Scandinavian Journal of Rheumatology","volume":" ","pages":"1-9"},"PeriodicalIF":1.5,"publicationDate":"2026-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148449051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Large-vessel vasculitis with mediastinitis after acupuncture: a case report.","authors":"K Naito, H Yorifuji, Y Katada, M Naito","doi":"10.1080/03009742.2026.2692304","DOIUrl":"https://doi.org/10.1080/03009742.2026.2692304","url":null,"abstract":"","PeriodicalId":21424,"journal":{"name":"Scandinavian Journal of Rheumatology","volume":" ","pages":"1-2"},"PeriodicalIF":1.5,"publicationDate":"2026-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148405823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sámi psoriatic arthritis patients in northern Norway receive less conventional synthetic disease-modifying anti-rheumatic drug treatment and have more arthritis, axial symptoms, and joint damage.","authors":"N Panagiotopoulos, M I Rosic, A R Broderstad, G Haugeberg, G Ø Eilertsen","doi":"10.1080/03009742.2026.2687239","DOIUrl":"10.1080/03009742.2026.2687239","url":null,"abstract":"<p><strong>Objectives: </strong>To compare Sámi and non-Sámi patients with psoriatic arthritis (PsA) and evaluate potential differences in treatment and joint damage.</p><p><strong>Method: </strong>A total of 424 adult PsA patients meeting the ClASsification for Psoriatic ARthritis (CASPAR) criteria were recruited from the Norwegian Arthritis Registry and hospitals in northern Norway. A questionnaire from the SAMINOR (a study in regions with Sámi and Norwegian populations) was used to identify Sámi and non-Sámi patients. Demographic and clinical characteristics, joint damage, and disease-modifying anti-rheumatic drug treatment data were compared between the groups. Binary logistic regression was used to adjust for age and gender differences.</p><p><strong>Results: </strong>Sixty Sámi and 364 non-Sámi patients were identified, and the groups were comparable in demographic characteristics and disease activity measurements. Sámi patients experienced more joint damage than non-Sámi patients (42% vs 26%, p = 0.010), and the highest rate was observed among Sámi men (p = 0.005). Sámi patients also had a higher prevalence of arthritis and axial involvement (92% vs 76%, p = 0.007 vs 32% vs 20%, p = 0.033). In addition, Sámi men showed significant underutilization of conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) (83% vs 92%, p = 0.031), particularly methotrexate (68% vs 90%, p = 0.002).</p><p><strong>Conclusion: </strong>Sámi PsA patients show higher rates of axial involvement, arthritis, and joint damage than their non-Sámi peers. Furthermore, Sámi patients demonstrate underutilization of csDMARDs. These findings underscore the importance of implementing culturally adapted healthcare strategies to improve treatment outcomes for Sámi patients with PsA.</p>","PeriodicalId":21424,"journal":{"name":"Scandinavian Journal of Rheumatology","volume":" ","pages":"1-9"},"PeriodicalIF":1.5,"publicationDate":"2026-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148376565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}